Novel targets in the treatment of neuroendocrine tumors: RBP2

Retinoblastoma binding protein 2, also known as RBP2, JARID1A or KDM5A, is an H3K4 demethylase implicated in a variety of non-neuroendocrine, and more recently, neuroendocrine tumors (NETs). NETs are tumors that form from neuroendocrine cells in tissues of the GI tract, endocrine pancreas, lung, ski...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of endocrine oncology Vol. 4; no. 1; pp. 31 - 41
Main Authors Maggi, Elaine C, Crabtree, Judy S
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.03.2017
Subjects
Cancer
carcinoid
Cell cycle
Cyclin-dependent kinases
Deoxyribonucleic acid
DNA
Drug resistance
Epigenetics
Gene expression
Intellectual disabilities
JARID1A
KDM5A
Kinases
Localization
Lung cancer
NET
neuroendocrine
Neuroendocrine tumors
Notch
pNET
Proteins
RBP2
Retina
Retinoblastoma
small cell lung carcinoma/SCLC
Telomerase
Online AccessGet full text

Cover

More Information
Summary:Retinoblastoma binding protein 2, also known as RBP2, JARID1A or KDM5A, is an H3K4 demethylase implicated in a variety of non-neuroendocrine, and more recently, neuroendocrine tumors (NETs). NETs are tumors that form from neuroendocrine cells in tissues of the GI tract, endocrine pancreas, lung, skin and other tissues. RBP2 is expressed at abnormally high levels in NETs and recent work demonstrates that modulation of RBP2 and impacts end points of tumorigenesis. Interestingly, the demethylase activity of RBP2 is not exclusively responsible for these changes, as RBP2's binding partners may mediate its activity in a tissue- or context-dependent manner. Here, we discuss the features of RBP2 and its role in cell cycle regulation, angiogenesis and drug resistance in cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:2045-0869
2045-0877
DOI:10.2217/ije-2016-0022